Why did you start this company?
“We had been working on the core technology for many years inside of a development partner, and had an opportunity to license most of the technology. It was a natural step to found InSitu Biologics given the work we had done, knowledge we had gained and the potential for a drug-eluting material to be available as a technology platform..”
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
What specific need/problem are you seeking to address in healthcare?
“We are seeking to reduce the systemic treatment of focal pain in the post-operative setting. Our product could greatly reduce the use of opiate based treatments, and stall the use of opiates for regional pain in children and young adults.”
What does your product do? How does it work?
“Our product elutes bupivacaine from a ph-neutral biohydrogel. Onset is nearly immediate, and the analgesic effect lasts 96-110 hours in pre-clinical tests. We have more bupivacaine in the bloodstream at 96 hours than the leading, and only FDA cleared product – Exparel – has at 12 hours. We have no toxicity or foreign body reaction. Completely innocuous.”
Is this your first healthcare startup? What’s your background in healthcare?
“I have not had a ‘job’ since 1991… I am an early employee of Microvena, founded Vascular Dynamics, ViaMedics, Image Guided Neurologix, Eight Medical, The Vasclip Company, among others. I have an MBA with an emphasis on finance, and my undergraduate degree is a BS with a major in Physical Education.”
What is your company’s business model?
“We intend to develop, clinically test and license sustained release products for the treatment of many diseases and conditions. Pain is our focus today, and we intend to pursue treatments for rheumatoid arthritis, and other costly, debilitating conditions.”
Who is your customer? How do you generate revenue?
“Our customer will be pharmaceutical, biopharma, and biological companies that take products to the market place.”
Do you have clinical validation for your product?
“We have GLP studies and are preparing for a Phase 1 Clinical Study.”
